3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
4
Active not recruiting
4
Completed
3
Not yet recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
3
Conditions
Breast Neoplasms
234
Neoplasms
206
Carcinoma, Non-Small-Cell Lung
100
Colorectal Neoplasms
98
Prostatic Neoplasms
93
Lung Neoplasms
78
Multiple Myeloma
53
Melanoma
51
Pancreatic Neoplasms
50
Head and Neck Neoplasms
49
Neoplasm Metastasis
47
Leukemia, Myeloid, Acute
43
Carcinoma, Hepatocellular
43
Ovarian Neoplasms
39
Brain Neoplasms
39
Squamous Cell Carcinoma of Head and Neck
36
Recurrence
35
Glioblastoma
33
Uterine Cervical Neoplasms
32
Sarcoma
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Glioma
29
Lymphoma, Non-Hodgkin
28
Lymphoma
27
Colonic Neoplasms
27
Stomach Neoplasms
26
Carcinoma, Renal Cell
26
Lymphoma, Follicular
25
Esophageal Neoplasms
24
Rectal Neoplasms
23
Interventions
pembrolizumab
1
lenvatinib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Diabetes Mellitus, Insulin-Dependent, 12
×
90 days
×
Clear all
NCT04305054
2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
335 enrolled
NCT04253080
2026-05-20
ENZYMELA
Assistance Publique - Hôpitaux de Paris
Phase NA
Completed
127 enrolled
NCT03293784
2026-03-30
TICIMEL
Institut Claudius Regaud
Phase 1
Completed
33 enrolled